• MapLight Therapeutics separated Chief Financial Officer Vishwas Setia, effective immediately on June 18, 2026, following a review of a human resources violation.
• The departure was described as unrelated to financial or operating results, internal controls, clinical programs, or financial reporting practices.
• Chief Administrative and Accounting Officer Jonathan Gillis was appointed interim chief financial officer, interim principal financial officer, effective June 18, 2026.
• Gillis will continue to serve as principal accounting officer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-276065), on June 18, 2026, and is solely responsible for the information contained therein.